Lara  Smith Weber net worth and biography

Lara Smith Weber Biography and Net Worth

Lara Smith Weber has served as Chief Financial Officer since January 2026. 

Ms. Smith Weber brings more than 20 years of financial leadership experience across medtech, biotech, and other growth-oriented industries. She has a strong track record of building disciplined financial organizations, supporting transitions into commercial-stage operations, and guiding companies through periods of operational scale with increasing regulatory and public-market complexity. 

Most recently, Ms. Smith Weber served as Chief Financial Officer of Inari, where she completed multiple financings, strengthened the company’s capital structure, and built financial systems and processes to support a growing organization. Previously, she was Chief Financial Officer of ONWARD Medical, a publicly traded medtech company listed on Euronext. Earlier in her career, Ms. Smith Weber served as U.S. Chief Financial Officer and Head of Commercial Finance at MorphoSys, where she played a key role in preparing the organization for and operating as a commercial-stage company. 

She holds bachelor’s degrees in German Studies and Electrical Engineering, a master’s degree in Electrical Engineering from Stanford University, and an MBA from IMD in Switzerland.

What is Lara Smith Weber's net worth?

The estimated net worth of Lara Smith Weber is at least $14.84 thousand as of June 8th, 2026. Ms. Smith Weber owns 20,000 shares of Fractyl Health stock worth more than $14,836 as of August 28th. This net worth approximation does not reflect any other assets that Ms. Smith Weber may own. Learn More about Lara Smith Weber's net worth.

How do I contact Lara Smith Weber?

The corporate mailing address for Ms. Smith Weber and other Fractyl Health executives is 17 Hartwell Avenue, Lexington, MA 02421, United States. Fractyl Health can also be reached via phone at 781-902-8800 and via email at [email protected]. Learn More on Lara Smith Weber's contact information.

Has Lara Smith Weber been buying or selling shares of Fractyl Health?

Lara Smith Weber has not been actively trading shares of Fractyl Health during the past quarter. Most recently, on Monday, June 8th, Weber Lara Smith bought 20,000 shares of Fractyl Health stock. The stock was acquired at an average cost of $0.69 per share, with a total value of $13,800.00. Following the completion of the transaction, the chief financial officer now directly owns 20,000 shares of the company's stock, valued at $13,800. Learn More on Lara Smith Weber's trading history.

Who are Fractyl Health's active insiders?

Fractyl Health's insider roster includes Jay Caplan (https://www.linkedin.com/in/ian-sheffield-b2021a/), Harith Rajagopalan (CEO), Ajay Royan (Director), Ian Sheffield (Director), and Lara Smith Weber (CFO). Learn More on Fractyl Health's active insiders.

Are insiders buying or selling shares of Fractyl Health?

During the last twelve months, Fractyl Health insiders bought shares 6 times. They purchased a total of 181,909 shares worth more than $147,148.61. The most recent insider tranaction occured on June, 12th when Director Ajay Royan bought 23,000 shares worth more than $19,550.00. Insiders at Fractyl Health own 8.5% of the company. Learn More about insider trades at Fractyl Health.

Information on this page was last updated on 6/12/2026.

Lara Smith Weber Insider Trading History at Fractyl Health

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/8/2026Buy20,000$0.69$13,800.0020,000View SEC Filing Icon  
See Full Table

Lara Smith Weber Buying and Selling Activity at Fractyl Health

This chart shows Weber Lara Smith's buying and selling at Fractyl Health by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Fractyl Health Company Overview

Fractyl Health logo
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
Read More

Today's Range

Now: $0.74
Low: $0.74
High: $0.76

50 Day Range

MA: $0.75
Low: $0.66
High: $0.91

2 Week Range

Now: $0.74
Low: $0.38
High: $2.45

Volume

56,479 shs

Average Volume

3,196,592 shs

Market Capitalization

$117.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.32